First Time Loading...
A

Apogee Therapeutics Inc
NASDAQ:APGE

Watchlist Manager
Apogee Therapeutics Inc
NASDAQ:APGE
Watchlist
Price: 51.17 USD -4.8% Market Closed
Updated: May 17, 2024

Intrinsic Value

APGE's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Apogee Therapeutics Inc is a US-based company operating in Biotechnology industry. [ Read More ]

The intrinsic value of one APGE stock under the Base Case scenario is 7.02 USD. Compared to the current market price of 51.17 USD, Apogee Therapeutics Inc is Overvalued by 86%.

Key Points:
APGE Intrinsic Value
Base Case
7.02 USD
Overvaluation 86%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation Backtest
Apogee Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling APGE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Apogee Therapeutics Inc

Provide an overview of the primary business activities
of Apogee Therapeutics Inc.

What unique competitive advantages
does Apogee Therapeutics Inc hold over its rivals?

What risks and challenges
does Apogee Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Apogee Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Apogee Therapeutics Inc.

Provide P/S
for Apogee Therapeutics Inc.

Provide P/E
for Apogee Therapeutics Inc.

Provide P/OCF
for Apogee Therapeutics Inc.

Provide P/FCFE
for Apogee Therapeutics Inc.

Provide P/B
for Apogee Therapeutics Inc.

Provide EV/S
for Apogee Therapeutics Inc.

Provide EV/GP
for Apogee Therapeutics Inc.

Provide EV/EBITDA
for Apogee Therapeutics Inc.

Provide EV/EBIT
for Apogee Therapeutics Inc.

Provide EV/OCF
for Apogee Therapeutics Inc.

Provide EV/FCFF
for Apogee Therapeutics Inc.

Provide EV/IC
for Apogee Therapeutics Inc.

Show me price targets
for Apogee Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Apogee Therapeutics Inc?

How accurate were the past Revenue estimates
for Apogee Therapeutics Inc?

What are the Net Income projections
for Apogee Therapeutics Inc?

How accurate were the past Net Income estimates
for Apogee Therapeutics Inc?

What are the EPS projections
for Apogee Therapeutics Inc?

How accurate were the past EPS estimates
for Apogee Therapeutics Inc?

What are the EBIT projections
for Apogee Therapeutics Inc?

How accurate were the past EBIT estimates
for Apogee Therapeutics Inc?

Compare the revenue forecasts
for Apogee Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Apogee Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Apogee Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Apogee Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Apogee Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Apogee Therapeutics Inc with its peers.

Analyze the financial leverage
of Apogee Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Apogee Therapeutics Inc.

Provide ROE
for Apogee Therapeutics Inc.

Provide ROA
for Apogee Therapeutics Inc.

Provide ROIC
for Apogee Therapeutics Inc.

Provide ROCE
for Apogee Therapeutics Inc.

Provide Gross Margin
for Apogee Therapeutics Inc.

Provide Operating Margin
for Apogee Therapeutics Inc.

Provide Net Margin
for Apogee Therapeutics Inc.

Provide FCF Margin
for Apogee Therapeutics Inc.

Show all solvency ratios
for Apogee Therapeutics Inc.

Provide D/E Ratio
for Apogee Therapeutics Inc.

Provide D/A Ratio
for Apogee Therapeutics Inc.

Provide Interest Coverage Ratio
for Apogee Therapeutics Inc.

Provide Altman Z-Score Ratio
for Apogee Therapeutics Inc.

Provide Quick Ratio
for Apogee Therapeutics Inc.

Provide Current Ratio
for Apogee Therapeutics Inc.

Provide Cash Ratio
for Apogee Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Apogee Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Apogee Therapeutics Inc?

What is the current Free Cash Flow
of Apogee Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Apogee Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Apogee Therapeutics Inc

Current Assets 398.4m
Cash & Short-Term Investments 395.5m
Other Current Assets 3m
Non-Current Assets 3m
PP&E 2.6m
Other Non-Current Assets 401k
Current Liabilities 20.6m
Accounts Payable 2.1m
Accrued Liabilities 18.4m
Non-Current Liabilities 933k
Other Non-Current Liabilities 933k
Efficiency

Earnings Waterfall
Apogee Therapeutics Inc

Revenue
0 USD
Operating Expenses
-93m USD
Operating Income
-93m USD
Other Expenses
9m USD
Net Income
-84m USD

Free Cash Flow Analysis
Apogee Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

APGE Profitability Score
Profitability Due Diligence

Apogee Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Apogee Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

APGE Solvency Score
Solvency Due Diligence

Apogee Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Apogee Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

APGE Price Targets Summary
Apogee Therapeutics Inc

Wall Street analysts forecast APGE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for APGE is 87.52 USD with a low forecast of 75.75 USD and a high forecast of 99.75 USD.

Lowest
Price Target
75.75 USD
48% Upside
Average
Price Target
87.52 USD
71% Upside
Highest
Price Target
99.75 USD
95% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Apogee Therapeutics Inc

Ownership

APGE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

APGE Price
Apogee Therapeutics Inc

1M 1M
-1%
6M 6M
+180%
1Y 1Y
+201%
3Y 3Y
+201%
5Y 5Y
+201%
10Y 10Y
+201%
Annual Price Range
51.17
52w Low
15
52w High
69.8
Price Metrics
Average Annual Return
N/A
Standard Deviation of Annual Returns
N/A
Max Drawdown -39%
Shares Statistics
Market Capitalization 2.9B USD
Shares Outstanding 56 367 800
Percentage of Shares Shorted 12.69%

APGE Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Apogee Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.9B USD

Dividend Yield

0%

Description

Apogee Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 27,000 full-time employees. The company went IPO on 2023-07-14. Apogee Therapeutics, Inc. is a biotechnology company. The firm is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.

Contact

MASSACHUSETTS
Waltham
221 Crescent St., Building 17, Suite 102b
+16503945230
https://apogeetherapeutics.com

IPO

2023-07-14

Employees

27 000

Officers

CEO & Director
Dr. Michael Thomas Henderson M.D.
Chief Financial Officer
Ms. Jane Pritchett V. Henderson
Chief Medical Officer
Dr. Carl Linden Dambkowski M.D.
Chief Technical Officer
Dr. Rebecca Dabora Ph.D.
Vice President of Investor Relations
Ms. Noel Kurdi
General Counsel
Mr. Matthew Batters J.D.
Show More
VP & Head of People
Ms. Emily Cox
Senior Vice President of Clinical Operations
Ms. Wendy Aspden-Curran
Senior VP and Head of Regulatory Affairs & Toxicology
Dr. Drew Badger Ph.D.
Senior Vice President of Finance
Ms. Monica Forbes
Show Less

See Also

Discover More
What is the Intrinsic Value of one APGE stock?

The intrinsic value of one APGE stock under the Base Case scenario is 7.02 USD.

Is APGE stock undervalued or overvalued?

Compared to the current market price of 51.17 USD, Apogee Therapeutics Inc is Overvalued by 86%.